Navigation Links
EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
Date:11/10/2008

ibition of the mTOR/rictor pathway. The Akt-mTOR pathway is the most frequently mutated pathway in human tumors and mutations have been shown to promote tumor progression and decrease survival in cancer patients. EntreMed Vice President and Chief Medical Officer, Carolyn F. Sidor, M.D., M.B.A., commented on the study, "We are pleased to have met the primary efficacy endpoint in the first stage of this study. We are now considering whether to continue the current study or pursue additional options such as a randomized Phase 2 study in patients with non-small cell lung cancer. We will continue to collect data over the next few months from patients participating in this trial to determine the most efficient path forward in this indication."

Alimta(R) is a registered trademark of its owner and is not a registered trademark of EntreMed, Inc.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Pr
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
2. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
5. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
6. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
7. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
8. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
9. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
10. World Think Tank on Type 1 Diabetes Meets in Miami
11. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. (PRWEB) , ... August 31, 2015 , ... ... this year to bring together supply chain risk management and resiliency practitioners with ... develop and share best practices, and be recognized for their innovations and performance ...
(Date:8/31/2015)... 31, 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: ... the Company,s lead antibody, HuMab 5B1, will be garnering ... during the upcoming World Molecular Imaging Congress (WMIC) being ... 2015. Researchers from the Department of Radiology at Memorial ... the use of MabVax,s lead antibody as a PET ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Israel Biomedical Sensors Market - Growth, Trends & Forecasts ... The Israel Biomedical Sensors market is estimated at $0.19 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/31/2015)... Portage Biotech Inc. ("Portage" or "the Company") (OTC Market: ... that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. (PPL) ... Investigational New Drug (IND) application for the topical treatment ... a study in a rat model of dry eye ... and a more rapid onset of action than 0.1% ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3
... 2011 Ardea Biosciences, Inc. (Nasdaq: RDEA ... underwritten public offering of 2,750,000 shares of its common ... $26.00 per share. The gross proceeds to Ardea from ... deducting the underwriting discount and other estimated offering expenses ...
... 2011 CSL Behring , a global leader ... of CSL Limited (ASX:CSL), has awarded advocacy ... the Local Empowerment for Advocacy Development (LEAD) program. LEAD ... to helping people who use plasma-derived or recombinant therapies ...
... 20, 2011 Bacterin International Holdings, Inc. ("Bacterin") ... it has closed on the Bridge Bank, N.A. revolving accounts ... that was announced on November 22, 2010.  The financing, which ... has a 2 year term and carries an interest rate ...
Cached Biology Technology:Ardea Biosciences Prices Public Offering of Common Stock 2Ardea Biosciences Prices Public Offering of Common Stock 3CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington 2CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington 3CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington 4Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank 2Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank 3
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
(Date:8/18/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) has ... Authentication & Identification Market: Focus On Modality, Motility ... report to their offering. The ... expected to grow at an estimated CAGR of ... $25 billion (approximately) by 2020 as per the ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... Tourists wanting to watch and swim with dolphins are now ... protect both the animals and the local communities whose livelihoods ... off the coast of Zanzibar has found that the many ... preventing them from resting, feeding and nurturing their young. , ...
... More than 1600 basic research scientists who study ... expected to attend the 51st Annual Drosophila ... Representatives of the media are invited to ... workshop sessions. Eligible media will receive complimentary registration (see ...
... the Energy Biosciences Institute (EBI) at the University ... nematodes in the first reported nematode survey of ... biofuels. Lead researcher Tesfamariam Mekete, a U ... first step was to identify potential pathogenic nematodes ...
Cached Biology News:Thrill-seeking holiday-makers are putting dolphins at risk 2Genetics Society of America's 51st Annual Drosophila Research Conference 2Genetics Society of America's 51st Annual Drosophila Research Conference 3Genetics Society of America's 51st Annual Drosophila Research Conference 4First parasitic nematodes reported in biofuel crops 2
Recombinant Rat Leptin, Ultra Pure...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: